Literature DB >> 23283457

Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects.

Heitor de Sá Gonçalves1, Maria Araci de Andrade Pontes, Samira Bührer-Sékula, Rossilene Cruz, Paulo Cesar Almeida, Maria Elisabete Amaral de Moraes, Gerson Oliveira Penna.   

Abstract

This study sought to verify the correlation between leprosy types and the adverse effects of treatment drugs. This quantitative, prospective, nested study was developed at the Dona Libânia Dermatology Centre in Fortaleza, Brazil. Data were collected from November 2007-November 2008. During this period, 818 leprosy patients were diagnosed and began treatment. Forty patients with tuberculoid leprosy (TT) were selected. Twenty patients followed a standard therapy of dapsone and rifampicin and 20 were administered dapsone, rifampicin and clofazimine (U-MDT). Twenty patients with borderline lepromatous (BL) and lepromatous leprosy (LL) were also selected and treated with U-MDT. All of the subjects received six doses. With the exception of haemolytic anaemia, there was a low incidence of adverse effects in all the groups. We did not observe any differences in the incidence of haemolytic anaemia or other side effects across groups of patients with TT, BL or LL treated with U-MDT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23283457     DOI: 10.1590/s0074-02762012000900013

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  6 in total

1.  Clinical and Histopathological Response to Multidrug Therapy in Paucibacillary Leprosy at the end of 6 Months: A Prospective Observational Study from Eastern India.

Authors:  Indrashis Podder; Abanti Saha; Debabrata Bandyopadhyay
Journal:  Indian J Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.494

2.  Leprosy reactions: The predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR).

Authors:  Emerith Mayra Hungria; Samira Bührer-Sékula; Regiane Morillas de Oliveira; Lúcio Cartaxo Aderaldo; Araci de Andrade Pontes; Rossilene Cruz; Heitor de Sá Gonçalves; Maria Lúcia Fernandes Penna; Gerson Oliveira Penna; Mariane Martins de Araújo Stefani
Journal:  PLoS Negl Trop Dis       Date:  2017-02-21

3.  Reply of the authors of the Continuing Medical Education article to Dr. Jaison Barreto and Dr. Laila Laguiche.

Authors:  Rossilente Conceiçao Cruz; Samira Bührer-Sékula; Maria Lúcia F Penna; Gerson de Oliveira Penna; Sinésio Talhari
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

4.  Multibacillary leprosy patients with high and persistent serum antibodies to leprosy IDRI diagnostic-1/LID-1: higher susceptibility to develop type 2 reactions.

Authors:  Danielle de Freitas Mizoguti; Emerith Mayra Hungria; Aline Araújo Freitas; Regiane Morillas Oliveira; Ludimila Paula Vaz Cardoso; Mauricio Barcelos Costa; Ana Lúcia Maroclo Sousa; Malcolm S Duthie; Mariane Martins Araújo Stefani
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11       Impact factor: 2.743

5.  Mycobacterium leprae-Specific Antibodies in Multibacillary Leprosy Patients Decrease During and After Treatment With Either the Regular 12 Doses Multidrug Therapy (MDT) or the Uniform 6 Doses MDT.

Authors:  Emerith M Hungria; Samira Bührer-Sékula; Regiane M Oliveira; Lúcio C Aderaldo; Maria Araci A Pontes; Rossilene Cruz; Heitor S de Gonçalves; Maria L F Penna; Gerson O Penna; Mariane M A Stefani
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

6.  Three drugs are unnecessary for treating paucibacillary leprosy-A critique of the WHO guidelines.

Authors:  Diana N J Lockwood; Saba Lambert; Aparna Srikantam; Joydeepa Darlong; V V Pai; C Ruth Butlin; Barbara de Barros; Edessa Negera; Stephen L Walker
Journal:  PLoS Negl Trop Dis       Date:  2019-10-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.